AR117770A1 - Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos - Google Patents

Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos

Info

Publication number
AR117770A1
AR117770A1 ARP200100028A ARP200100028A AR117770A1 AR 117770 A1 AR117770 A1 AR 117770A1 AR P200100028 A ARP200100028 A AR P200100028A AR P200100028 A ARP200100028 A AR P200100028A AR 117770 A1 AR117770 A1 AR 117770A1
Authority
AR
Argentina
Prior art keywords
polypeptides
modified
agonize
bind
activated
Prior art date
Application number
ARP200100028A
Other languages
English (en)
Spanish (es)
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of AR117770A1 publication Critical patent/AR117770A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ARP200100028A 2019-01-07 2020-01-06 Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos AR117770A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07

Publications (1)

Publication Number Publication Date
AR117770A1 true AR117770A1 (es) 2021-08-25

Family

ID=69374426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100028A AR117770A1 (es) 2019-01-07 2020-01-06 Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos

Country Status (15)

Country Link
US (1) US20220089667A1 (enExample)
EP (1) EP3908596A1 (enExample)
JP (2) JP7594161B2 (enExample)
KR (1) KR20210113265A (enExample)
CN (1) CN113924311A (enExample)
AR (1) AR117770A1 (enExample)
AU (1) AU2020206672B2 (enExample)
BR (1) BR112021012294A2 (enExample)
CA (1) CA3125529A1 (enExample)
CL (1) CL2021001779A1 (enExample)
IL (1) IL284633A (enExample)
MX (1) MX2021008147A (enExample)
SG (1) SG11202106700WA (enExample)
TW (1) TWI874345B (enExample)
WO (1) WO2020146221A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
AU2019376076B9 (en) 2018-11-08 2025-06-19 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
WO2021041206A1 (en) 2019-08-23 2021-03-04 Synthorx, Inc. Il-15 conjugates and uses thereof
TW202124385A (zh) 2019-09-10 2021-07-01 美商欣爍克斯公司 治療自體免疫疾病之il-2接合物及使用方法
JP2023531876A (ja) * 2020-06-30 2023-07-26 ジーアイ イノベーション， インコーポレイテッド 抗ｌａｇ－３抗体とｉｌ－２とを含む融合タンパク質及びその使用
MX2022016532A (es) * 2020-07-02 2023-04-12 Inhibrx Inc Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
EP4259213A4 (en) * 2020-12-09 2024-11-20 Asher Biotherapeutics, Inc. TARGETED CYTOKINE CONSTRUCT FOR MANIPULATED CELL THERAPY
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
AU2022252307A1 (en) * 2021-03-31 2023-10-12 Anwita Biosciences, Inc. Fusion proteins, pharmaceutical compositions, and therapeutic applications
WO2023004305A1 (en) * 2021-07-20 2023-01-26 Inhibrx, Inc. Cd8-targeted modified il-2 polypeptides and uses thereof
CA3225092A1 (en) * 2021-07-20 2023-01-26 John C. Timmer Cd8-binding polypeptides and uses thereof
WO2023034740A1 (en) * 2021-08-30 2023-03-09 Inhibrx, Inc. Nkp46-binding polypeptides and uses thereof
TW202328171A (zh) * 2021-08-30 2023-07-16 美商英伊布里克斯公司 靶向NKp46之經修飾之IL-2多肽及其用途
CN118019849A (zh) * 2021-09-26 2024-05-10 上海药明生物技术有限公司 Il-2变体及其融合蛋白
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
JP2025528019A (ja) * 2022-07-28 2025-08-26 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２プロサイトカイン抗体融合タンパク質

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005040395A1 (en) 2003-10-22 2005-05-06 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
ES2694564T3 (es) * 2011-02-10 2018-12-21 Roche Glycart Ag Polipéptidos de interleucina-2 mutantes
KR102677704B1 (ko) * 2012-05-30 2024-06-21 추가이 세이야쿠 가부시키가이샤 표적 조직 특이적 항원 결합 분자
EA201992609A1 (ru) * 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг Слитые белки, содержащие интерлейкин-2, и их применения
AU2017206618A1 (en) * 2016-01-11 2018-07-05 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
CN115073581A (zh) * 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
KR102619015B1 (ko) * 2017-03-15 2023-12-28 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2018184965A1 (en) * 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
FI3606955T3 (fi) * 2017-04-05 2025-01-08 Hoffmann La Roche Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita
CN111010866A (zh) * 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
US11542312B2 (en) * 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies

Also Published As

Publication number Publication date
BR112021012294A2 (pt) 2021-09-08
KR20210113265A (ko) 2021-09-15
US20220089667A1 (en) 2022-03-24
TW202043259A (zh) 2020-12-01
MX2021008147A (es) 2021-08-11
WO2020146221A1 (en) 2020-07-16
JP2025013911A (ja) 2025-01-28
JP2022516557A (ja) 2022-02-28
JP7594161B2 (ja) 2024-12-04
AU2020206672B2 (en) 2025-10-02
TWI874345B (zh) 2025-03-01
CA3125529A1 (en) 2020-07-16
SG11202106700WA (en) 2021-07-29
AU2020206672A1 (en) 2021-07-15
IL284633A (en) 2021-08-31
EP3908596A1 (en) 2021-11-17
CL2021001779A1 (es) 2022-03-04
CN113924311A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
AR117770A1 (es) Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
AR122863A1 (es) Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
ECSP21056325A (es) Compuesto heterocíclico y su uso
BR112021018770A2 (pt) Métodos e dispositivos de terapia digital personalizada
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
CL2018002140A1 (es) Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos
CO2019008873A2 (es) Polipéptidos de unión al receptor de transferrina diseñados.
MX2020014243A (es) Neoantigenos y usos de los mismos.
MX2023013883A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos para su uso.
CO2021012230A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
MX2019005325A (es) Matriz para el crecimiento de celulas.
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
AR101844A1 (es) Anticuerpos y conjugados modificados genéticamente con cisteína
MX2020011788A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
PE20110020A1 (es) Inmunomodulacion mediante el uso de celulas madres de la placenta
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
MX2019006286A (es) Metodos para determinar la dosificacion en la terapia celular.
CL2017001903A1 (es) Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante
AR079505A1 (es) Uso de cry1da en combinacion con cry1ca para el manejo de insectos resistentes
AR108166A1 (es) Subunidad grande de la proteína rubisco modificada
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii